The purpose of this study is to see if the human papillomavirus vaccine can help prevent these abnormal cells from coming back after treatment. The study will look at how long it takes for the abnormal cells to return in people who receive the vaccine compared to those who receive placebo. The vaccine is designed to work against specific types of human papillomavirus that are known to cause these cell changes.

During the study, people will receive three doses of either the vaccine or placebo over a period of time. They will then be followed for up to five years to check if the abnormal cells come back. The study will also look at whether the vaccine helps clear the human papillomavirus from the body, whether it prevents new abnormal cells from developing in other areas, and whether it reduces the risk of developing cancer related to human papillomavirus. Safety will be monitored throughout the study by tracking any unwanted effects that may occur.

The purpose of the study is to see how effective the combination of these treatments is in helping patients become free of HSIL after 48 weeks. Participants will be randomly assigned to receive either the combination of Sinecatechins and the chemical procedure or the chemical procedure alone. The study will monitor the participants over a period of time to see if the lesions improve or disappear and if they stay away.

Participants in the study will apply the Sinecatechins ointment to the affected area as directed, in addition to undergoing the chemical procedure. The study aims to determine if adding the ointment helps more patients achieve a complete or partial response, meaning the lesions either return to normal or become less severe. The trial will last for about 48 weeks, with some flexibility in timing, to assess the long-term effectiveness of the treatment.

The purpose of the study is to see if using vaginal estradiol before a colposcopic examination can improve the diagnosis of precancerous lesions in the cervix. A colposcopy is a procedure where a doctor uses a special magnifying device to look at the cervix more closely. The study will involve participants receiving either the estradiol treatment or a placebo for a short period before their colposcopy. The researchers will then assess the visibility of the cervix during the examination and the representation of cervical tissue in biopsies, which are small samples of tissue taken for closer examination.

Throughout the study, the researchers will also monitor any side effects reported by participants during the pretreatment phase. They will evaluate the presence of more severe cell changes, known as CIN2+, in the biopsies. The study aims to reduce the burden of cervical disease and prevent the progression to cervical cancer by improving diagnostic accuracy. The trial is expected to run until December 2025, with recruitment having started in August 2023.

Participants in the study will receive pembrolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will follow a single-arm design, meaning all participants will receive the same treatment without a comparison group. The treatment period is expected to last up to six months. Throughout the study, participants will be monitored for changes in their lesions and any side effects they may experience. The study aims to see if pembrolizumab can help reduce or eliminate the lesions and prevent them from progressing to more serious conditions like cancer.

The study will also track the presence of HPV in participants and assess whether the virus is still detectable after treatment. By the end of the study, researchers hope to gather valuable information on the potential benefits of pembrolizumab for treating these specific HPV-related lesions. This could lead to new treatment options for individuals with similar conditions in the future.